A Phase 2/3 interventional study of Andecaliximab and Placebo in Ulcerative Colitis, sponsored by Gilead Sciences. Terminated at 88 sites in 23 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-10.
Sponsored by Gilead Sciences · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.
Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 163rd largest by enrollment of the 499 interventional ones that give a count, is one of 33 that started in 2015, is one of 16 in phase 2/3, and was the 228th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in United States
Ages 16–80
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–85
University of Minnesota · Sites in United States
Ages 18+
Muhammad N Aslam, MD · Sites in United States
Ages 18–80
Vanda Pharmaceuticals · Sites in United States
Ages 18–75
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
615 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 87 · Phase 2 173 · Phase 3 132 · Phase 4 33
First in 1995; this study’s year is marked. 33 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 76 across the 499 interventional studies, 198 across the 113 observational. Of the 407 that completed or were terminated, 192 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
332 of 615 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Gilead Sciences has 7 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
55 of the studies in Colitis, Ulcerative with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 55 to your calendar (.ics) → With an account.
Among the 615 studies in Colitis, Ulcerative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are as follows: 1) To evaluate the efficacy of andecaliximab to induce endoscopy, rectal bleeding, and stool frequency (EBS) clinical remission at Week 8 (Cohort 1); 2) To evaluate the efficacy of andecaliximab to maintain EBS clinical remission at Week 52 (Cohort 2); and 3) To evaluate the safety and tolerability of andecaliximab. The study will consist of 3 parts: Induction Phase (Cohort 1), Maintenance Phase (Cohort 2), and an optional Extended Treatment Phase.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive andecaliximab 150 mg administered via subcutaneous (SC) injection alternating with matching placebo weekly for a total of 4 doses of andecaliximab. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
Biological: Andecaliximab · Biological: Placebo
Participants will receive andecaliximab 150 mg administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
Biological: Andecaliximab
Participants will receive placebo matched to andecaliximab administered via SC injection once weekly for a total of 8 doses. Based on Week 8 assessment results, participants will either continue in Blinded Maintenance Treatment phase or will be offered Open-Label andecaliximab 150 mg administered via SC injection weekly for up to Week 51.
Biological: Andecaliximab · Biological: Placebo
Andecaliximab 150 mg administered via SC injection
Also known as: GS-5745
Placebo matched to andecaliximab administered via SC injection
For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8
EBS clinical remission was defined as an endoscopic subscore of 0 or 1 (endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]); rectal bleeding subscore of 0 (rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes); and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1 (stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal).
Time frame: Week 8
For Cohort 1, Percentage of Participants With MCS Remission at Week 8
The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. The MCS remission was defined as a MCS of ≤ 2 points and no individual subscore \> 1 point. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.
Time frame: Week 8
For Cohort 1, Percentage of Participants With MCS Response at Week 8
The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening. The MCS response was defined as a MCS reduction of ≥ 3 points and at least 30% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1.
Time frame: Week 8
For Cohort 1, Percentage of Participants With Endoscopic Remission at Week 8
Endoscopic remission was defined as endoscopic subscore of 0. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).
Time frame: Week 8
For Cohort 1, Percentage of Participants With Endoscopic Response at Week 8
Endoscopic response was defined as endoscopic subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).
Time frame: Week 8
For Cohort 1, Percentage of Participants With Mucosal Healing as Determined by the Geboes Histologic Scoring System at Week 8
Mucosal healing was defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. When measured by the Geboes histologic scoring system, it was the selection of the following combined scores of ≤ 3 for Grade 0 (Structural Architectural Change), ≤ 1 for Grade 1 (Chronic Inflammatory Infiltrate), ≤ 3 for Grade 2A (Lamina Propria Eosinophils), and 0 for Grade 2B (Lamina Propria Neutrophils), Grade 3 (Neutrophils in Epithelium), Grade 4 (Crypt Destruction), and Grade 5 (Erosion or Ulceration). Total Geboes histologic score ranged from 0 to 22, with higher scores indicating greater disease severity.
Time frame: Week 8
For Cohort 1, Percentage of Participants With MCS Remission (Alternative Definition) at Week 8
The MCS remission (alternative definition) was defined as a rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA subscore (range: 0 to 3 with higher score indicating the severe disease) of 0, and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]) of 0 or 1 for an overall MCS of ≤ 1. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.
Time frame: Week 8
Participants were enrolled at study sites in South Africa, Europe, North America, and Asia Pacific. The first participant was screened on 15 September 2015. The last study visit occurred on 22 November 2016.
| Milestone | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| Started | 54 | 56 | 55 |
| Completed | 52 | 52 | 53 |
| Not completed | 2 | 4 | 2 |
| Withdrew: Adverse event | 1 | 3 | 0 |
| Withdrew: Withdrew consent | 1 | 1 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 1 |
| Milestone | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| Started | 20 | 16 | 18 |
| Completed | 0 | 0 | 0 |
| Not completed | 20 | 16 | 18 |
| Withdrew: Study terminated by sponsor | 17 | 11 | 15 |
| Withdrew: Disease worsening | 2 | 2 | 3 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Disposition error | 0 | 2 | 0 |
| Milestone | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| Started | 32 | 35 | 34 |
| Completed | 0 | 0 | 0 |
| Not completed | 32 | 35 | 34 |
| Withdrew: Study terminated by sponsor | 25 | 29 | 28 |
| Withdrew: Withdrew consent | 3 | 4 | 2 |
| Withdrew: Adverse event | 2 | 1 | 3 |
| Withdrew: Investigator's discretion | 2 | 1 | 1 |
EBS clinical remission was defined as an endoscopic subscore of 0 or 1 (endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]); rectal bleeding subscore of 0 (rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes); and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1 (stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal).
| percentage of participants | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| For Cohort 1, Percentage of Participants With EBS Clinical Remission at Week 8 | 7.4 (2.1 to 17.9) | 1.8 (0.0 to 9.6) | 7.3 (2.0 to 17.6) |
The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. The MCS remission was defined as a MCS of ≤ 2 points and no individual subscore \> 1 point. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.
| percentage of participants | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| For Cohort 1, Percentage of Participants With MCS Remission at Week 8 | 7.4 (2.1 to 17.9) | 1.8 (0.0 to 9.6) | 7.3 (2.0 to 17.6) |
The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening. The MCS response was defined as a MCS reduction of ≥ 3 points and at least 30% from baseline, with an accompanying decrease in rectal bleeding subscore of ≥ 1 point or an absolute rectal bleeding subscore of 0 or 1.
| percentage of participants | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| For Cohort 1, Percentage of Participants With MCS Response at Week 8 | 46.3 (32.6 to 60.4) | 30.4 (18.8 to 44.1) | 30.9 (19.1 to 44.8) |
Endoscopic remission was defined as endoscopic subscore of 0. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| For Cohort 1, Percentage of Participants With Endoscopic Remission at Week 8 | 3.7 (0.5 to 12.7) | 0.0 (0.0 to 6.4) | 5.5 (1.1 to 15.1) |
Endoscopic response was defined as endoscopic subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).
| percentage of participants | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| For Cohort 1, Percentage of Participants With Endoscopic Response at Week 8 | 18.5 (9.3 to 31.4) | 7.1 (2.0 to 17.3) | 14.5 (6.5 to 26.7) |
Mucosal healing was defined as elimination of ulcers/erosion, elimination of crypt destruction, elimination of intraepithelial neutrophils, elimination of lamina propria neutrophils, and reduction in lamina propria chronic inflammatory cells to at most a mild increase. When measured by the Geboes histologic scoring system, it was the selection of the following combined scores of ≤ 3 for Grade 0 (Structural Architectural Change), ≤ 1 for Grade 1 (Chronic Inflammatory Infiltrate), ≤ 3 for Grade 2A (Lamina Propria Eosinophils), and 0 for Grade 2B (Lamina Propria Neutrophils), Grade 3 (Neutrophils in Epithelium), Grade 4 (Crypt Destruction), and Grade 5 (Erosion or Ulceration). Total Geboes histologic score ranged from 0 to 22, with higher scores indicating greater disease severity.
| percentage of participants | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| For Cohort 1, Percentage of Participants With Mucosal Healing as Determined by the Geboes Histologic Scoring System at Week 8 | 18.0 (8.6 to 31.4) | 13.7 (5.7 to 26.3) | 22.0 (11.5 to 36.0) |
The MCS remission (alternative definition) was defined as a rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA subscore (range: 0 to 3 with higher score indicating the severe disease) of 0, and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]) of 0 or 1 for an overall MCS of ≤ 1. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating disease worsening.
| percentage of participants | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo |
|---|---|---|---|
| For Cohort 1, Percentage of Participants With MCS Remission (Alternative Definition) at Week 8 | 1.9 (0.0 to 9.9) | 0.0 (0.0 to 6.4) | 0.0 (0.0 to 6.5) |
Collected over Blinded Induction Phase: First dose of study drug to Week 8; Blinded Maintenance Phase: First dose of study drug up to approximately 39 weeks plus 30 days; Open-Label Maintenance Phase: First dose of open-label andecaliximab up to approximately 41 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Blinded Induction Phase: Andecaliximab Every 2 Weeks | 0/54 (0%) | 0/54 (0%) | 24/54 (44.4%) |
| Blinded Induction Phase: Andecaliximab Every Weeks | 0/56 (0%) | 2/56 (3.6%) | 31/56 (55.4%) |
| Blinded Induction Phase: Placebo | 0/55 (0%) | 1/55 (1.8%) | 26/55 (47.3%) |
| Blinded Maintenance Phase: Andecaliximab Every 2 Weeks | 0/20 (0%) | 1/20 (5%) | 12/20 (60%) |
| Blinded Maintenance Phase: Andecaliximab Every Week | 0/16 (0%) | 2/16 (12.5%) | 12/16 (75%) |
| Blinded Maintenance Phase: Placebo | 0/18 (0%) | 1/18 (5.6%) | 13/18 (72.2%) |
| Open-Label Maintenance Phase From Andecaliximab Every 2 Weeks | 0/32 (0%) | 1/32 (3.1%) | 9/32 (28.1%) |
| Open-Label Maintenance Phase From Andecaliximab Every Week | 0/35 (0%) | 3/35 (8.6%) | 6/35 (17.1%) |
| Open-Label Maintenance Phase From Placebo | 0/34 (0%) | 2/34 (5.9%) | 12/34 (35.3%) |
| Event | Blinded Induction Phase: Andecaliximab Every 2 Weeks | Blinded Induction Phase: Andecaliximab Every Weeks | Blinded Induction Phase: Placebo | Blinded Maintenance Phase: Andecaliximab Every 2 Weeks | Blinded Maintenance Phase: Andecaliximab Every Week | Blinded Maintenance Phase: Placebo | Open-Label Maintenance Phase From Andecaliximab Every 2 Weeks | Open-Label Maintenance Phase From Andecaliximab Every Week | Open-Label Maintenance Phase From Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Angina pectorisCardiac disorders | 0/54 | 1/56 | 0/55 | 0/20 | 1/16 | 0/18 | 0/32 | 0/35 | 0/34 |
| Inguinal herniaGastrointestinal disorders | 0/54 | 0/56 | 0/55 | 0/20 | 1/16 | 0/18 | 0/32 | 0/35 | 0/34 |
| Anal abscessInfections and infestations | 0/54 | 0/56 | 1/55 | 0/20 | 0/16 | 1/18 | 0/32 | 0/35 | 0/34 |
| Colitis ulcerativeGastrointestinal disorders | 0/54 | 0/56 | 0/55 | 1/20 | 0/16 | 0/18 | 1/32 | 1/35 | 1/34 |
| Biliary dilatationHepatobiliary disorders | 0/54 | 0/56 | 0/55 | 0/20 | 0/16 | 0/18 | 0/32 | 0/35 | 1/34 |
| Cerebrovascular accidentNervous system disorders | 0/54 | 0/56 | 0/55 | 0/20 | 0/16 | 0/18 | 0/32 | 0/35 | 1/34 |
| Cytomegalovirus infectionInfections and infestations | 0/54 | 0/56 | 0/55 | 0/20 | 0/16 | 0/18 | 0/32 | 1/35 | 0/34 |
| NephrolithiasisRenal and urinary disorders | 0/54 | 0/56 | 0/55 | 0/20 | 0/16 | 0/18 | 0/32 | 1/35 | 0/34 |
| AnaemiaBlood and lymphatic system disorders | 0/54 | 1/56 | 0/55 | 0/20 | 0/16 | 0/18 | 0/32 | 0/35 | 0/34 |
| Event | Blinded Induction Phase: Andecaliximab Every 2 Weeks | Blinded Induction Phase: Andecaliximab Every Weeks | Blinded Induction Phase: Placebo | Blinded Maintenance Phase: Andecaliximab Every 2 Weeks | Blinded Maintenance Phase: Andecaliximab Every Week | Blinded Maintenance Phase: Placebo | Open-Label Maintenance Phase From Andecaliximab Every 2 Weeks | Open-Label Maintenance Phase From Andecaliximab Every Week | Open-Label Maintenance Phase From Placebo |
|---|---|---|---|---|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 2/54 | 3/56 | 1/55 | 2/20 | 1/16 | 4/18 | 1/32 | 1/35 | 3/34 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/54 | 3/56 | 3/55 | 1/20 | 3/16 | 3/18 | 0/32 | 2/35 | 1/34 |
| AnaemiaBlood and lymphatic system disorders | 4/54 | 4/56 | 2/55 | 3/20 | 1/16 | 0/18 | 0/32 | 1/35 | 3/34 |
| NasopharyngitisInfections and infestations | 2/54 | 2/56 | 2/55 | 0/20 | 2/16 | 2/18 | 1/32 | 1/35 | 0/34 |
| HypophosphataemiaMetabolism and nutrition disorders | 0/54 | 1/56 | 0/55 | 0/20 | 2/16 | 0/18 | 1/32 | 0/35 | 0/34 |
| HeadacheNervous system disorders | 2/54 | 4/56 | 1/55 | 0/20 | 2/16 | 1/18 | 1/32 | 0/35 | 0/34 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/54 | 3/56 | 1/55 | 0/20 | 2/16 | 0/18 | 1/32 | 0/35 | 0/34 |
| AcneSkin and subcutaneous tissue disorders | 0/54 | 1/56 | 0/55 | 0/20 | 2/16 | 0/18 | 0/32 | 0/35 | 0/34 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/54 | 1/56 | 2/55 | 0/20 | 1/16 | 2/18 | 1/32 | 0/35 | 0/34 |
| DizzinessNervous system disorders | 0/54 | 1/56 | 1/55 | 0/20 | 1/16 | 2/18 | 0/32 | 0/35 | 0/34 |
Safety Analysis Set included all participants who received at least 1 dose of study drug in the Blinded Induction Phase.
| Age, Continuous(years) | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo | Total |
|---|---|---|---|---|
| Mean | 44 ± 14.1 | 43 ± 13.2 | 43 ± 12.8 | 43 ± 13.3 |
| Sex: Female, Male(Participants) | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo | Total |
|---|---|---|---|---|
| Female | 19 | 18 | 24 | 61 |
| Male | 35 | 38 | 31 | 104 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo | Total |
|---|---|---|---|---|
| Race — White | 48 | 48 | 45 | 141 |
| Race — Black | 4 | 3 | 3 | 10 |
| Race — Asian | 2 | 4 | 4 | 10 |
| Race — Native Hawaiian or Pacific Islander | 0 | 0 | 1 | 1 |
| Race — Not Permitted | 0 | 0 | 1 | 1 |
| Race — Other | 0 | 1 | 1 | 2 |
| Race/Ethnicity, Customized(Participants) | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo | Total |
|---|---|---|---|---|
| Ethnicity — Hispanic or Latino | 0 | 0 | 2 | 2 |
| Ethnicity — Not Hispanic or Latino | 54 | 56 | 51 | 161 |
| Ethnicity — Not Permitted | 0 | 0 | 2 | 2 |
| Region of Enrollment(Participants) | Andecaliximab Every 2 Weeks | Andecaliximab Weekly | Placebo | Total |
|---|---|---|---|---|
| Romania | 4 | 2 | 1 | 7 |
| Hungary | 1 | 2 | 2 | 5 |
| United States | 20 | 20 | 21 | 61 |
| Czechia | 1 | 0 | 1 | 2 |
| Ukraine | 3 | 3 | 3 | 9 |
| United Kingdom | 2 | 2 | 2 | 6 |
| Switzerland | 0 | 2 | 0 | 2 |
| Russia | 2 | 4 | 4 | 10 |
| New Zealand | 0 | 3 | 1 | 4 |
| Canada | 0 | 2 | 3 | 5 |
| South Korea | 2 | 3 | 2 | 7 |
| Latvia | 1 | 0 | 0 | 1 |
| Netherlands | 0 | 1 | 0 | 1 |
| Belgium | 1 | 3 | 2 | 6 |
| Ireland | 0 | 1 | 0 | 1 |
| Taiwan | 0 | 1 | 0 | 1 |
| Poland | 11 | 4 | 8 | 23 |
| Italy | 0 | 2 | 2 | 4 |
| South Africa | 1 | 1 | 0 | 2 |
| Slovakia | 1 | 0 | 0 | 1 |
| Australia | 3 | 0 | 2 | 5 |
| Bulgaria | 1 | 0 | 0 | 1 |
| France | 0 | 0 | 1 | 1 |
Ran from Sep 2015 to primary completion in Sep 2016, 12 months.
Results were first posted in Apr 2019, 2 years 7 months after primary completion. A results delay was requested in Feb 2017.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Andecaliximab